NCT00078468已完成2 期
A Phase 2 Open-Label Multicenter Study Of The Garft Inhibitor AG2037 In Patients With Metastatic Colorectal Cancer Who Failed Treatment With A 5-Fluorouracil/Leucovorin Regimen.
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- Pfizer
- 入组人数
- 56
- 试验地点
- 4
- 主要终点
- To determine the overall objective response rate (complete and partial responses) of AG-2037 in patients with metastatic colorectal cancer who failed treatment with 5FU/LV regimen and up to one other chemotherapeutic regimen.
研究概览
简要总结
To determine the response rate in patients with metastatic colorectal cancer who failed treatment with a 5-Fluorouracil/Leucovorin regimen and up to one other chemotherapeutic regimen (not including adjuvant chemotherapy).
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically or cytologically confirmed metastatic adenocarcinoma of the colon or rectum
- •Stage IV or recurrent disease
- •Measurable disease
- •Disease progression or recurrence during or after completion of prior first-line chemotherapy with fluorouracil and leucovorin calcium (5-FU/LV)
- •Prior irinotecan or oxaliplatin as part of the 5-FU/LV regimen or as subsequent therapy allowed
- •Only 2 prior regimens for metastatic disease allowed
- •One additional regimen as adjuvant therapy allowed provided patient remained disease-free for > 6 months after completion of therapy*
- •Newer, targeted investigational agents (e.g., cetuximab or bevacizumab) are not
- •counted as a chemotherapeutic regimen unless used in combination with a cytotoxic regimen NOTE: *If evidence of failure occurred within < 6 months after completion of adjuvant therapy, patients may have received only 1 additional regimen for metastatic disease
- •No active brain metastases (requiring treatment or progressing)
排除标准
- •History of blood transfusion within 14 days
- •Need of concurrent Administration of allopurinol
- •History of Radiotherapy or Chemotherapy within 4 weeks
- •Any psychological or sociological condition, addidtive disorder or family problems that might preclude compliance with the protocol
- •Any unstable or severe intercurrent medical condition that in the opinion of th einvestigator might interfere with achievement of study objectives
- •Receipt of an investigational agent within 28 days prior to first day of dosing with AG-2037
- •Pregnant or breast feeding
- •Previous treatment with GARFT inhibitors
- •History of a malignancy (other than colorectal cancer) excpet those treated with curative intent for skin cancer (other than melanoma) or in situ breast or cervical cancer or those treated with curative intent for any other cancer with no evidence of disease for 5 years
- •Active brain metastases (requiring treatment or progression)
结局指标
主要结局
To determine the overall objective response rate (complete and partial responses) of AG-2037 in patients with metastatic colorectal cancer who failed treatment with 5FU/LV regimen and up to one other chemotherapeutic regimen.
次要结局
- To estimate time to progression (TTP).
- To evaluate the overall survival (1-year) of patients treated with AG-2037.
- To assess changes in patient reported outcomes using health-related quality of life questionnaires.
- To evaluate the safety of AG-2037.
- To evalutate the PK and PD of AG-2037.
- To correlate the various genetic markers of MTAP, folate and purine metabolism with clinical response.
研究者
研究点 (4)
Loading locations...
相似试验
招募中
2 期
TATE and Pembrolizumab (MK3475) in mCRC and NSCLCColorectal Cancer Lung CancerNCT04701476Teclison Ltd.110
已完成
2 期
Phase 2b Study of VELCADE Alone and VELCADE Plus Irinotecan in Patients With Relapsed or Refractory Colorectal CarcinomaColorectal CarcinomaNCT00051987Millennium Pharmaceuticals, Inc.175
已完成
2 期
A Study of BIBW 2992 (Afatinib) in Patients With Metastatic Colorectal CancerColorectal NeoplasmsNCT01152437Boehringer Ingelheim94
进行中（未招募）
2 期
The Efficacy and Safety of HLX208 in Metastatic Colorectal Cancer (mCRC) With BRAF V600E MutationMetastatic Colorectal CancermCRCNCT05127759Shanghai Henlius Biotech25
已完成
2 期
Safety and Efficacy of Folfox6 + Cetuximab Versus Folfiri +Cetuximab in Patients With Metastatic Colorectal CancerMetastatic Colorectal CancerNCT00286130Central European Cooperative Oncology Group150